Pharmacist-driven renal medication dosing intervention in a primary care patient-centered medical home

Pharmacotherapy

Volumn 34, Issue 12, 2014, Pages 1330-1335

  Barnes, Kelli D ^a   Tayal, Neeraj H ^b   Lehman, Amy M ^a   Beatty, Stuart J ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

chronic kidney disease; electronic medical record; patient centered medical home; pharmacist; population management; primary care

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ANTITHROMBOCYTIC AGENT;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE CALCULATION; DOSE KIDNEY FUNCTION RELATION; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HOME CARE; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICATION COMPLIANCE; MEDICATION THERAPY MANAGEMENT; PATIENT CARE; PATIENT COMPLIANCE; PHARMACIST; PRESCRIPTION; PRIMARY MEDICAL CARE; ELDERLY CARE; KIDNEY FAILURE, CHRONIC; NURSING HOME; OUTCOME ASSESSMENT; PRIMARY HEALTH CARE; STANDARDS; UNITED STATES;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; FEMALE; HEALTH SERVICES FOR THE AGED; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; NURSING HOMES; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACISTS; PLATELET AGGREGATION INHIBITORS; PRIMARY HEALTH CARE; UNITED STATES;

EID: 84919779224     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1508     Document Type: Article

References (26)

1. Long CL, Raebel MA, Price DW, Magid DJ,. Compliance with dosing guidelines in patients with chronic kidney disease. Ann Pharmacother 2004; 38: 853-8.
2. The National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 2003; 41 (4 suppl 3): S1-91.
3. The National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive Agents in chronic kidney disease. Am J Kidney Dis 2004; 45 (5 suppl 1): S1-290.
4. Jurkovitz CT, Elliott DE, Li S, et al. Physician utilization, risk factor control, and CKD progression among participants in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2011; 59: S24-33.
5. Shahinian VB, Saran R,. The role of primary care in the management of the chronic kidney disease population. Adv Chronic Kidney Dis 2010; 17: 246-53.
6. Allen AS, Forman JP, Oray EJ, et al. Primary care management of chronic kidney disease. J Gen Intern Med 2010; 26: 386-92.
7. Patel HR, Pruchnicki MC, Hall LE,. Assessment for chronic kidney disease service in high-risk patients at community health clinics. Ann Pharmacother 2005; 39: 22-7.
8. Israni A, Korzelius C, Townsend R, et al. Management of chronic kidney disease in an academic primary care clinic. Am J Nephrol 2003; 23: 47-54.
9. Chase HS, Radhakrishnan J, Shirazian S, et al. Under-documentation of chronic kidney disease in the electronic health record in outpatients. J Am Med Inform Assoc 2010; 17: 588-94.
10. Mason NA,. Polypharmacy and medication-related complications in the chronic kidney disease patient. Curr Opin Nephrol Hypertens 2011; 20: 492-7.
11. Hassan Y, Al-Ramahi RJ, Aziz NA, Ghazali R,. Impact of a renal drug dosing service on dose adjustment in hospitalized patients with chronic kidney disease. Ann Pharmacother 2009; 43: 1598-605.
12. National Committee for Quality Assurance. Patient-Centered medical home. Available from http://www.ncqa.org/tabid/631/default.aspx. Accessed April 2, 2013.
13. Centers for Medicare and Medicaid Services. Accountable Care Organizations, 2013. Available from http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ACO/index.html?redirect=/aco/. Accessed April 20, 2013.
14. Van Dijk EA, Drabbe NRG, Kruijtbosch M, et al. Drug dosage adjustments according to renal function at hospital discharge. Ann Pharmacother 2006; 40: 1254-60.
15. Stemer G, Lemmens-Gruber R,. Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: a systematic literature review. BMC Nephrol 2011; 12: 35.
16. Grabe DW, Low CL, Bailie GR, Eisele G,. Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist. Clin Nephrol 1997; 47: 117-21.
17. Pai AB, Boyd A, Depczynski J, et al. Reduced drug use and hospitalization rates in patients undergoing hemodialysis who received pharmaceutical care: a 2-year, randomized, controlled study. Pharmacotherapy 2009; 29: 1433-40.
18. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999; 130: 461-70.
19. The National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 suppl 1): S1-266.
20. Micromedex Healthcare Series [Internet database]. Greenwood Village, CO: Thomson Healthcare. Updated periodically.
21. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Neprhon 1976; 16: 31-41.
22. Brady M, O'Donoghue D,. The role of primary care in managing chronic kidney disease. Br J Gen Pract 2010; 60: 396-7.
23. Olesen JB, Lip GYH, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012; 367: 625-35.
24. Patient Protection and Affordable Care Act, 2010, Pub. L. No. 111-148, §2702, 124 Stat. 119, 318-319.
25. Institute for Health Technology Transformation. Population health management: a roadmap for provider-based automation in a new era of healthcare, 2012. Available from https://iht2populationhealthreport.questionpro.com/. Accessed June 18, 2012.
26. The American Recovery and Reinvestment Act of 2009. Available from BILLS-111hr1enr.pdf. Accessed July 10, 2012.